Expect Industry To Step Up Drug Pricing Self-Regulation In 2017 – PwC
Executive Summary
As industry begins to organize around broader self-regulation on drug pricing, PwC Partner Rick Judy expects pharma companies to announce more social contracts with consumers. Industry self-regulation on prices is one of 10 top health issues for 2017 identified by the consulting firm.
You may also be interested in...
Trump Win Is False Security For Drug Makers, Allergan CEO Warns
Industry should act on drug pricing now while there is a post-election reprieve, Allergan CEO Brent Saunders said during the Forbes Healthcare Summit. Trump is a populist who will jump on the next big pricing scandal, he said.
The Outcomes-Based Reimbursement Experiment
US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.
Calif. Prop 61 Raises Industry Concerns Over Ripple Effect
Industry executives are speaking out against the measure that would require California state agencies to pay no more than the US Department of Veterans Affairs pay for drugs.